Page 2 - Cipla Results

Cipla Q4 result: Profit rises 30% to ₹1,222 cr; special dividend declared

Cipla Q4 FY25 result: Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share

Q4 results today: Cipla, Hero Moto, Airtel, Siemens, Tata Motors on May 13

Q4 FY25 company results: GAIL (India), Aditya Birla Capital, and GlaxoSmithKline Pharmaceuticals will also be releasing their Jan-March quarter results on May 13

Stocks to watch today, May 13: Tata Motors, Airtel, GAIL, Cipla, Tata Steel

In the previous trading session, Sensex jumped 2,975.43 points, or 3.7 per cent, to close at 82,429.90 levels. The Nifty50 closed at 24,924.7, up by 916.7 points, or 3.8 per cent.

Cipla share price jumps 5% as USFDA okays cancer drug Paclitaxel

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10

Cipla Q3 result: PAT soars 48.7% to Rs 1,570.5 cr , revenue grows 7.1%

Cipla's stock was up 3 per cent during the day's trade on the BSE in the afternoon

Cipla Q3 result: Profit up 49% at Rs 1,571 cr on strong demand in N America

The company's consolidated net profit increased nearly 49 per cent to Rs 1,571 crore ($181.6 million) in the October-December quarter,

Markets Today: Cipla, Bajaj Auto Q3; RBI; Nasdaq; DeepSeek; CLN Energy IPO

At 6:31 AM, GIFT Nifty futures pointed to a positive start, trading 76 points higher at 22,922

Here's why Cipla share price zoomed 10% on October 31; check details

The uptick in Cipla share price came after the United States Food and Drug Administration (USFDA) on Wednesday classified Goa facility as Voluntary Action Indicated (VAI)

Cipla Q2 results: Net profit up 17%, income from operations at Rs 7,051 cr

Drug major Cipla on Tuesday reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the second quarter ended September 2024, driven by robust sales across markets. The company had reported a net profit of Rs 1,115 crore in the July-September quarter of the last fiscal. Its total income from operations rose to Rs 7,051 crore in the second quarter compared to Rs 6,490 crore in the year-ago period, Cipla said in a regulatory filing. "In Q2 FY25, we recorded a revenue growth of 9 per cent over the last year with a highest-ever EBITDA margin of 26.7 per cent driven by mix and other operational efficiencies," Cipla MD and Global CEO Umang Vohra said. The company's 'One-India' business was impacted during the quarter due to a changed seasonal pattern. However key chronic therapies in the branded prescription business continued to grow faster than the market, he added. The company's consumer health business grew at a strong 21 per cent year-on-year, Vohra said. "

Cipla drops over 3% ahead of Q2FY25 results; know what analysts expect

Shares of Cipla dropped 3.55 per cent at Rs 1,450 per share on the BSE in Tuesday's intraday trade

Cipla Q2 Preview: Analysts expect lukewarm growth in sales, profit

Analysts expect Cipla to register a low single digit rise in the topline and bottomline, with margins being impacted by modest sales in the US and domestic formulations

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Buy ideas for May 22: Britannia, Cipla; check target prices

Cipla was in a downtrend and corrected ~13 per cent in the recent fall. On the daily charts it formed an Inverted Head and Shoulders pattern which is a Trend reversal pattern

Bharti Airtel, Cipla, Paytm, Colgate among seven stocks to track on May 15

At 6:55 AM, GIFT Nifty futures was trading 73 points higher at 22,382.50 levels compared to Nifty50 futures, indicating a positive start for the bourses

Cipla surges 6% in weak market on upbeat management commentary

The management has guided 24.5 per cent-25.5 per cent Ebitda margin for FY25

Cipla Q4 results: Net profit soars 79% on strong India and US business

Eyes further market expansion and partnerships in FY25

Cipla Q4 results: Profit rises 78.5% to Rs 939 crore, revenue up 7%

Cipla Q4FY24 results: The company board has recommended a final dividend of Rs 13 per equity share, to be paid within 30 days from the date of the annual general meeting (AGM)

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

Sanofi, Cipla join hands to expand reach of CNS portfolio in India

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug